Rudolf Herbst
4PUBLICATIONS
54CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (4)
Sort by Publication Date:
|Jun 12, 2023
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.Reinhard Dummer, Pippa Corrie, Ralf Gutzmer
|Apr 07, 2023
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG.Cindy Franklin, Peter Mohr, Leonie Bluhm
|Apr 12, 2022
Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany.Peter Mohr, Emilie Scherrer, Chalid Assaf
|Feb 10, 2022
Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.Inês Pires da Silva, Tasnia Ahmed, Jennifer L McQuade
Pageof 1
Frequent Collaborators
3 joint publications
Selma Ugurel
3 joint publications
Michael Weichenthal
3 joint publications
Ralf Gutzmer
2 joint publications
Friedegund Meier
2 joint publications
Alexander Kreuter
2 joint publications
Jessica C Hassel
2 joint publications
James Larkin
2 joint publications
Patrick Terheyden
1 joint publications
Jennifer L McQuade
1 joint publications
Michele Maio
